

From the Editorial Board

Recognizing and Celebrating Innovation and Innovators in Biopharma Table of Contents for Special Edition of J. Commercial Biotechnology

Journal of Commercial Biotechnology (2021) 26(2), 1. doi: 10.5912/jcb983

“Introduction, Rationale and Commentary on Recognizing and Celebrating Innovation in Our Industry” – From the Editorial Board (Arthur A. Boni, Ph. D., Editor in Chief, Dennis M. Gross, Ph.D., Associate Editor, Moira A. Gunn, Ph. D. Associate Editor, and Daniel S. Levine, Editorial Opinion Contributor)

This introductory article summarizes our basis for recognition of innovative companies (past, present and emerging) in our industry, and summarizes the criterion that we are using to evaluate those organizations selected for contributing to innovation in the life sciences industry. We also develop and list both industry leaders, both pioneers and current, who we selected as members of the *JCB Innovators Hall of Fame – 2021*.

“Companies Recognized as Innovators for 2021 – From the Editorial Board (Arthur A. Boni, Ph. D., Editor in Chief, Dennis M. Gross, Ph.D., Associate Editor, Moira A. Gunn, Ph. D. Associate Editor, and Daniel S. Levine, Editorial Opinion Contributor)

Highlights selected companies that have been developing and launching transformative products and services for 2021, grouped according to the 4-quadrant innovation model of Boni and Joseph. Summaries are provided for those companies selected, and grouped according to our 4-quadrant innovation model: 1. direct innovation by startups/emerging companies/mature companies; 2. alliances and consortia; 3. corporate accelerators; and, 4. independent accelerators.

“INDUSTRY PERSPECTIVES AND COMMENTARY

From the Boardroom/Bioentrepreneurship Industry Perspectives: “Waiving COVID-19 Vaccine Patents: A Bad Idea and a Dangerous Precedent” (Peter J. Pitts, Robert Popovian, and Wayne Weingarden)

“Commentary & Book Review of “The Code Breaker: Jennifer Doudna, gene editing, and the future of the human race; by Walter Issacson (Simon & Schuster, 2021).”

With an Addendum – “Some pertinent, concluding comments on the importance of high-performance, diverse teams for founding, building, and growing successful biotechnology companies” (Arthur A. Boni).

“A Note on Corporate Open Innovation: Engagement with Startups” (Diana Joseph, Arthur A. Boni, and Dennis Abremski)

MINI-CASE STUDIES OF LIFE SCIENCES ORGANIZATIONS RECOGNIZED FOR PIVOTAL TRANSFORMATIVE INNOVATION: ACROSS THE LIFE CYCLE – PAST, PRESENT AND FUTURE

Building technology enabled platform companies in Biopharma – a perspective on early-stage value creation from Millennium, Alnylam, Moderna, & Kymira” (Yuanxin Rong)

Bridge BIO (Daniel S. Levine)

Berkeley Lights (Daniel S. Levine)

**Illumina Accelerator: Next Gen Corporate Accelerator
with a Customer-Creation Focus (Diana Joseph and
Amanda Cashin)**

Abridge (Sandeep Konam and Shivdev Rao)

**A Case Study – NeuBase Therapeutics (Dietrich A.
Stephan)**